Bavarian Nordic's $160M FDA speedy review voucher sale shows prices keep rising amid concerns over key program
The value of priority review vouchers (PRVs) appears to be on the rise as concerns mount over declining supplies following the sunset of the rare pediatric disease PRV program.
The value of priority review vouchers (PRVs) appears to be on the rise as concerns mount over declining supplies following the sunset of the rare pediatric disease PRV program.
